Qarziba Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The qarziba market research report is one of a series of new reports that provides qarziba market statistics, including qarziba industry global market size, regional shares, competitors with a qarziba market share, detailed qarziba market segments, market trends and opportunities, and any further data you may need to thrive in the qarziba industry. This qarziba market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to increasing pediatric cancer incidence, advancements in immunotherapy, regulatory approvals, and growing awareness. Major trends in the forecast period include increasing demand for targeted therapy, expansion into emerging markets, collaboration with research institutions, technological advancements, and regulatory approvals.

The increasing prevalence of cancer is expected to drive the growth of the Qarziba market. Several factors contribute to this rise, including an aging population, lifestyle changes such as smoking, poor diet, lack of physical activity, and genetic predispositions. Qarziba (dinutuximab beta) is used in pediatric oncology to treat high-risk neuroblastoma by targeting GD2-expressing cancer cells, enhancing immune-mediated tumor destruction, and reducing the risk of relapse in this aggressive form of cancer. For example, a report from the Australian Institute of Health and Welfare in August 2024 projected that by 2034, Australia would see about 209,000 new cancer diagnoses, a notable increase from the estimated 169,000 in 2024. This rise is a result of both population growth and increasing cancer rates, further driving the demand for Qarziba in the market.

A key trend in the Qarziba market is the strategic development of the drug to treat high-risk neuroblastoma, which helps establish a competitive edge. Qarziba works by targeting the GD2 antigen on cancer cells, boosting the immune system's ability to destroy tumor cells and improve survival outcomes. In August 2022, BeiGene Ltd., a Chinese biotechnology company, collaborated with EUSA Pharma, a UK-based pharmaceutical firm, to announce that the China National Medical Products Administration (NMPA) granted conditional approval for Qarziba to treat patients with high-risk neuroblastoma. This approval was specifically for patients aged 12 months and older who had undergone induction chemotherapy with at least a partial response, followed by myeloablative therapy and stem cell transplantation.

In July 2024, Farma Mondo Hong Kong Ltd., a China-based pharmaceutical company, entered into a partnership with Recordati UK Ltd. to distribute Qarziba in Hong Kong. As part of the agreement, Farma Mondo will assume the role of Marketing Authorization Holder (MAH), managing the commercial distribution of Qarziba, which is primarily used to treat high-risk neuroblastoma in children under five. Recordati UK Ltd., a UK-based pharmaceutical company, is collaborating with Farma Mondo in this distribution effort.

The key company operating in the qarziba market is EUSA Pharma (UK) Ltd.

North America was the largest region in the qarziba market in 2024. The regions covered in qarziba report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the qarziba market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Qarziba (dinutuximab beta) is a monoclonal antibody used for treating high-risk neuroblastoma in children. It specifically targets GD2, a molecule present on neuroblastoma cells, which helps the immune system recognize and destroy these cancer cells. Typically, Qarziba is part of a broader treatment plan that includes immunotherapy. It has been shown to enhance survival rates and lower the chances of relapse in pediatric patients with neuroblastoma.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Qarziba is primarily indicated for high-risk neuroblastoma and relapsed or refractory neuroblastoma. High-risk neuroblastoma is an aggressive cancer in children, often found in areas such as the adrenal glands, neck, chest, abdomen, or pelvis, and is frequently diagnosed at advanced stages. The drug is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is commonly used in hospitals and specialized oncology clinics.

The qarziba market consists of sales of monoclonal antibody therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.